Carregant...
A phase I study of CAR-T bridging HSCT in patients with acute CD19(+) relapse/refractory B-cell leukemia
Chimeric antigen receptor (CAR)-T cell therapy is a novel cellular immunotherapy for relapsed/refractory(R/R) B acute lymphoblastic leukemia (B-ALL). However, the survival duration of CAR-T cells in vivo is noteworthy, and in some cases recurrence occurs following CAR-T cell therapy. There is contro...
Guardat en:
| Publicat a: | Oncol Lett |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405367/ https://ncbi.nlm.nih.gov/pubmed/32774493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11881 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|